The final report on the anti-Kir4.1 antibodies in the patients with MS was carried out by Navas-Madroñal et al., wherein they attempted to replicate the association between the Kir4.1 antibodies and MS using three different approaches to overcome the technical limitations of a single technique [51]. Here, KCNJ10 is linked to myeloid sarcoma.